©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Sep 24, 2016; 6(3): 556-563
Published online Sep 24, 2016. doi: 10.5500/wjt.v6.i3.556
Published online Sep 24, 2016. doi: 10.5500/wjt.v6.i3.556
Tregs and kidney: From diabetic nephropathy to renal transplantation
Periklis Dousdampanis, Kostantina Trigka, Hemodialysis Unit, Kyanos Stavros, 26225 Patras, Greece
Athanasia Mouzaki, Laboratory of Immunohematology, Division of Hematology, Department of Internal Medicine, Medical School, University of Patras, 26504 Patras, Greece
Author contributions: Dousdampanis P, Trigka K and Mouzaki A wrote the paper.
Conflict-of-interest statement: None.
Correspondence to: Periklis Dousdampanis, MD, PhD, Consultant Nephrologist, Hemodialysis Unit, Kyanos Stavros, Germanou 115, 26225 Patras, Greece. dousdampanis@yahoo.gr
Telephone: +30-26-10243110 Fax: +30-26-10243139
Received: May 25, 2016
Peer-review started: May 26, 2016
First decision: July 6, 2016
Revised: July 14, 2016
Accepted: July 29, 2016
Article in press: August 1, 2016
Published online: September 24, 2016
Processing time: 120 Days and 16.7 Hours
Peer-review started: May 26, 2016
First decision: July 6, 2016
Revised: July 14, 2016
Accepted: July 29, 2016
Article in press: August 1, 2016
Published online: September 24, 2016
Processing time: 120 Days and 16.7 Hours
Core Tip
Core tip: This review brings together certain key studies on the role of regulatory T-cells (Tregs) in end-stage renal disease, diabetes and kidney transplantation, only to emphasize that many more studies are needed to elucidate the clinical significance and the therapeutic applications of Tregs.